^
Association details:
| Biomarker: | MYC rearrangement |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Regimen: | CARMEN (cisplatin + cyclophosphamide + cytarabine + doxorubicin hydrochloride + etoposide IV + methotrexate IV + Rituxan (rituximab) + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
181 | SAFETY AND EFFICACY OF THE “CARMEN” REGIMEN, A NEW DOSE-DENSE SHORT-TERM THERAPY IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA AND MYC REARRANGEMENT
Published date:
06/09/2021
Excerpt:
pts aged 18-80 years with BL or HGBCL and MYC rearrangement positive by FISH were treated with CARMEN regimen...18 (82%) HGBCL and 37 (90%) BL pts achieved a response, which was CR in 10 (45%) and 26 (63%) pts, respectively....CARMEN is a safe and active treatment both in HIV-negative and –positive pts with HGBCL and MYC rearrangement and BL.
